The points to consider while managing Systemic autoinflammatory diseases included 14 statements related to diagnosis, 10 on therapy, and 9 focused on long-term monitoring.
The European umbrella organization (EULAR) developed new points to consider for diagnosing, treating, and monitoring systemic autoinflammatory diseases. This was developed by a multidisciplinary task force from 7 European countries. The people taking part had expertise in pediatric and adult rheumatology. The group also included allied health professionals and patient representatives. The work was completed in line with EULAR standardized operating procedures.
What are Systemic autoinflammatory diseases (SAIDs)?
The aim was to establish evidence-based recommendations for the diagnosis, treatment, and monitoring of people with IL-1-mediated autoinflammatory diseases. Systemic autoinflammatory diseases (SAIDs) are a group of multi-system disorders caused by dysfunction in the innate immune system.‘Evidence-based recommendations for diagnosis, treatment, and monitoring of people with Interleukin-1 mediated autoinflammatory diseases were developed.’
A number of these are mediated by a cytokine called interleukin-1 (IL-1), including cryopyrin-associated periodic syndromes (CAPS), tumor necrosis factor receptor-associated periodic syndrome (TRAPS), mevalonate kinase deficiency (MKD), and deficiency of the IL-1 receptor antagonist (DIRA). These rare diseases usually start in early childhood with variable multiorgan involvement.The paper developed by EULAR and published in the issue of the Annals of Rheumatic Diseases includes five overarching principles and three sets of points to consider.
The principles say that a multidisciplinary team is required to evaluate and manage people with IL-1-mediated SAIDs, and that patients presenting with flares of unexplained systemic inflammation should receive a prompt diagnostic workup including genetic testing and screening for complications.
The goal of treatment is to control clinical signs and symptoms and normalize inflammation using a treat-to-target approach which requires long-term monitoring.
Guide for Diagnostic Evaluation, Treatment and Monitoring of SAIDS
The three sets of points to consider include 14 statements related to diagnosis, 10 on therapy, and 9 focused on long-term monitoring. For diagnosis, the points cover genetic and clinical workup for specific diseases.The statements on therapy give suggestions for the use of IL-1 blocking therapy, each supported by a grade of recommendation and level of supporting evidence. The 9 points to consider in monitoring touch on disease activity and burden, as well as the growth and development of children with SAIDs, and the risk of complications and infections. These also cover recommendations for immunizations.
Advertisement
Advertisement